Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: Correlation with psychopathology and cognition

Psychopharmacology

Volumn 232, Issue 1, 2015, Pages 165-172

  Lv, Meng Han ^a   Tan, Yun Long ^a   Yan, Shao Xiao ^a   Tian, Li ^b   Chen, Da Chun ^a   Tan, Shu Ping ^a   Wang, Zhi Ren ^a   De Yang, Fu ^a   Yoon, Jin H ^c   Zunta Soares, Giovana B ^c   Soares, Jair C ^c   Zhang, Xiang Yang ^a,c  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF HELSINKI   (Finland)

^c University of Texas Harris County Psychiatric Center   (United States)

Author keywords

Cognition; Cytokine; Immune; Interleukin; Psychopathology; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; BLOOD; CHRONIC DISEASE; COGNITION; COHORT ANALYSIS; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HUMAN; MALE; MENTAL DISEASE; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGY; SCHIZOPHRENIA; TIME;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; CHRONIC DISEASE; COGNITION; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOPATHOLOGY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939897968     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3650-y     Document Type: Article

References (57)

1. Altamura AC, Buoli M, Pozzoli S (2014) Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci 68(1):21-36
2. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell'osso B, Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Das UN, Meyer U, Müller N, Kanchanatawan B, Maes M (2013) Immunoinflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42:1-4
3. Baune BT, Konrad C, Grotegerd D, Suslow T, Ohrmann P, Bauer J, Arolt V, Heindel W, Domschke K, Schöning S, Rauch AV, Sehlmeyer C, Kugel H, Dannlowski U (2012) Tumor necrosis factor gene variation predicts hippocampus volume in healthy individuals. Biol Psychiatry 72(8):655-662
4. Beattie MS, Hermann GE, Rogers RC, Bresnahan JC (2002) Cell death in models of spinal cord injury. Prog Brain Res 137:37-47
5. Benros ME, Mortensen PB, Eaton WW (2012) Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci 1262:56-66
6. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML (2012) Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res 46(11):1421-1426
7. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, Lukic ML (2013) Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res 147(1):103-109
8. Citrome L, Meng XY, Hochfeld M (2011) Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res 131(1-3):75-81
9. Coelho FM, Reis HJ, Nicolato R, Romano-Silva MA, Teixeira MM, Bauer ME, Teixeira AL (2008) Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 15(2):140-144
10. Czerski PM, Rybakowski F, Kapelski P, Rybakowski JK, Dmitrzak-Weglarz M, Leszczyńska-Rodziewicz A, Słopień A, Skibińska M, Kaczmarkiewicz-Fass M, Hauser J (2008) Association of tumor necrosis factor-308G/A promoter polymorphism with schizophrenia and bipolar affective disorder in a Polish population. Neuropsychobiology 57:88-94
11. Dean B, Gibbons AS, Tawadros N, Brooks L, Everall IP, Scarr E (2013) Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders. Mol Psychiatry 18(7):767-773
12. Debnath M, Mitra B, Bera NK, Chaudhuri TK, Zhang YP (2013) Lack of association of IL-6 (-174 G > C) and TNF-α (-238 G > A) variants with paranoid schizophrenia in Indian Bengalee population. Cytokine 61(2):455-458
13. Deverman BE, Patterson PH (2009) Cytokines and CNS development. Neuron 64(1):61-78
14. Di Nicola M, Cattaneo A, Hepgul N, Di Forti M, Aitchison KJ, Janiri L et al (2013) Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav Immun 31:90-95
15. Duan S, Xu Y, Chen W, Liu Z, Guo T, Gao J, Bian L, Zheng Y, Li X, Zhang X, Pan Y, Gu N, Feng G, He L (2004) No association between the promoter variants of tumor necrosis factor alpha (TNF-α) and schizophrenia in Chinese Han population. Neurosci Lett 366:139-143
16. Francesconi LP, Ceresér KM, Mascarenhas R, Stertz L, Gama CS, Belmonte-de-Abreu P (2011) Increased annexin-V and decreased TNF-alpha serum levels in chronic-medicated patients with schizophrenia. Neurosci Lett 502:143-146
17. Garay PA, McAllister AK (2010) Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Front Synaptic Neurosci 2:136
18. Gaulden J, Reiter JF (2008) Neur-ons and neur-offs: regulators of neural induction in vertebrate embryos and embryonic stem cells. Hum Mol Genet 17(R1):R60-R66
19. Jia P, Wang L, Meltzer HY, Zhao Z (2010) Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res 122(1-3):38-42
20. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
21. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2009) Cytokine changes and tryptophan metabolites in medication naïve and medication-free schizophrenic patients. Neuropsychobiology 59:123-129
22. Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157(5):683-694
23. Kunz M, Ceresér KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, Belmonte-de-Abreu PS, Kauer-Sant'Anna M, Kapczinski F, Gama CS (2011) Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and antiinflammatory balance. Rev Bras Psiquiatr 33(3):268-274
24. Lindenmayer JP, Grochowski S, Hyman RB (1994) Five factor model of schizophrenia: replication across samples. Schizophr Res 14(3):229-234
25. Mansur RB, Zugman A, Asevedo EM, da Cunha GR, Bressan RA, Brietzke E (2012) Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci 66(4):247-260
26. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45
27. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663-671
28. Morar B, Schwab SG, Albus M, Maier W, Lerer B, Wildenauer DB (2007) Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 144B:318-324
29. Muller N, Schwarz M (2006) Schizophrenia as an inflammation-mediateddysbalance of glutamatergic neurotransmission. Neurotox Res 10:131-148
30. Na KS, Jung HY, Kim YK (2014) The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 48:277-286
31. Nakajima A, Yamada K, Nagai T, Uchiyama T, Miyamoto Y, Mamiya T, He J, Nitta A, Mizuno M, Tran MH, Seto A, Yoshimura M, Kitaichi K, Hasegawa T, Saito K, Yamada Y, Seishima M, Sekikawa K, Kim HC, Nabeshima T (2004) Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 24(9):2212-2225
32. Naudin J, Capo C, Giusano B, Mège JL, Azorin JM (1997) A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 26(2-3):227-233
33. Naz N, Riaz M, Saleem M (2011) Potential role of Neuregulin 1 and TNF-alpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Mol Biol Rep 38:4709-4714
34. Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Noda Y, Nabeshima T (2007) Tumor necrosis factor-alpha and its inducer inhibit morphine-induced rewarding effects and sensitization. Biol Psychiatry 62(6):658-668
35. O'Brien SM, Scully P, Dinan TG (2008) Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations ofschizophrenia. Psychiatry Res 160(3):256-262
36. Pae CU, Chae JH, Bahk WM, Han H, Jun TY, Kim KS, Kwon YS, Serretti A (2003) Tumor necrosis factor-alpha gene polymorphism at position -308 and schizophrenia in the Korean population. Psychiatry Clin Neurosci 57(4):399-403
37. Pan W, Zadina JE, Harlan RE, Weber JT, Banks WA, Kastin AJ (1997) Tumor necrosis factor-alpha: a neuromodulator in the CNS. Neurosci Biobehav Rev 21(5):603-613
38. Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JC, Teixeira AL, Lobato MI, Walz JC, Belmonte-de-Abreu PS, Kauer-Sant'Anna M, Kapczinski F, Gama CS (2012) Similarities in serum oxidative stress markers and inflammatory cytokines in patientswith overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 46(6):819-824
39. Potvin S, Stip E, Sephery AA, Gendron A, Bah R, Kouassi E (2008) Inflammatory cytokines alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801-808
40. Richard MD, Brahm NC (2012) Schizophrenia and the immune system: pathophysiology, prevention, and treatment. Am J Health Syst Pharm 69(9):757-766
41. Rodriguez-Jimenez R, Bagney A, Mezquita L, Martinez-Gras I, Sanchez-Morla E, Mesa N, Ibañez M, Diez-Martin J, Jimenez-Arriero M, Lobo A, Santos J, Palomo T, PARG (2013) Cognition and the five-factor model of the Positive and Negative Syndrome Scale in schizophrenia. Schizophr Res 143(1):77-83
42. Sacchetti E, Bocchio-Chiavetto L, Valsecchi P, Scassellati C, Pasqualetti P, Bonvicini C, Corsini P, Rossi G, Cesana BM, Barlati S, Gennarelli M (2007) G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: meta-analysis plus association study. Brain Behav Immun 21:450-457
43. Saviouk V, Chow EWC, Bassett AS, Brzustowicz LM (2005) Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44. Mol Psychiatry 10:375-383
44. Schmitt A, Bertsch T, Tost H, Bergmann A, Henning U, Klimke A, Falkai P (2005) Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatr Dis Treat 1(2):171-177
45. Song C, Lin A, Kenis G, Bosmans E, Maes M (2000) Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophr Res 42(2):157-164
46. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP (2009) The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 65:481-488
47. Strieter RM, Kunkel SL, Bone RC (1993) Role of tumor necrosis factor-alpha in disease states, inflammation. Crit Care Med 21(10 Suppl): S447-S463
48. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, Stefanis CN (2001) Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 47:13-25
49. Tonelli LF, Postolache TT (2005) Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge. Neurol Res 27:679-684
50. Tourjman V, Kouassi É, Koué MÈ, Rocchetti M, Fortin-Fournier S, Fusar-Poli P, Potvin S (2013) Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr Res 151(1-3):43-47
51. Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D (2012) Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res 137(1-3):246-250
52. Watanabe Y, Muratake T, Kaneko N, Fukui N, Nara Y, Someya T (2007) No association between the tumor necrosis factor-alpha gene promoter polymorphisms and schizophrenia in a Japanese population. Psychiatry Res 153:1-6
53. Watanabe Y, Someya T, Nawa H (2010) Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 64(3):217-230
54. Xu HM, Wei J, Hemmings GP (1994) Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia. Br J Psychiatry 164:251-253
55. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC (2004) Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 65(7):940-947
56. Zhang XY, Cao LY, Song C, Wu GY, da Chen C, Qi LY, Wang F, Xiu MH, Chen S, Zhang Y, Lu L, Kosten TA, Kosten TR (2008) Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics. Psychopharmacology 201(3):383-389
57. Zhang XY, Tang W, Xiu MH, da Chen C, Yang FD, Tan YL, Wang ZR, Zhang F, Liu J, Liu L, Chen Y, Wen N, Kosten TR (2013) Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls. Brain Behav Immun 32:105-111